Erasca, Inc.

NASDAQ:ERAS

Biotechnology

Healthcare
$13.76 -0.14%

-$0.02 today

Market cap
$4.83B
Beta
0.73
P/E (TTM)
-15.3
EPS (TTM)
-$0.91
52W Low $1.21High $24.28

Volume 8.94M

Average 6.79M

ERAS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Erasca, Inc.NASDAQ: ERAS

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 344.24M shares rose 21.3% year over year, ahead of the +9.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at +32.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.3% holds above the trailing-twelve-month pace of +9.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
344.24M+10.6% QoQ
Last fiscal yearDec 2025
283.53M+21.3% YoY
LTMSep 2026
310.86M+9.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.3%——
1 year+21.3%——
3-year CAGR+32.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
283.53M USD
Year-over-year change
+21.3%
4-year CAGR
+24.2%

Weighted Avg Shares vs competitors

How ERAS compares with its peers on the latest reported figures

  • ERAS's LTM Sep 2026 weighted avg shares of 310.86M shares is the 2nd highest of the 9 companies compared; the peer median is 90.72M shares.
  • Its year-over-year change of +9.7% is the 6th highest of 9, against a peer median of +15.1%.
  • Over three fiscal years its annual growth of +32.5% compares with a peer median of +22.6%.
ERAS Competitors Peer median
Weighted Avg Shares for ERAS and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026345.71M +7.2%+16.4%
ERASErasca, Inc.LTM Sep 2026310.86M +9.7%+32.5%
RVMDRevolution Medicines, Inc.LTM Jun 2026197.09M +10.9%+33.1%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.85M +4.6%+28.8%
KURAKura Oncology, Inc.LTM Mar 202687.97M +1.1%+9.4%
VSTMVerastem, Inc.LTM Mar 202680.25M +101.5%+62.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding ERAS) 90.72M+15.1%+22.6%

Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue829K2.64M3.73M03.11M
Gross Profit(829K)(2.64M)(3.73M)0(3.11M)
Gross Margin—————
Research & Development73.92M112.46M103.82M115.36M92.85M
Selling, General & Admin22.62M32.99M37.7M41.73M38.55M
Operating Expenses124.05M244.81M137.79M179.59M128.3M
Depreciation & Amortization829K2.64M3.73M3.81M3.11M
EBITDA(121.94M)(240.16M)(121.31M)(153.28M)(121.44M)
EBITDA Margin—————
Operating Income(124.88M)(247.45M)(141.53M)(179.59M)(131.41M)
Operating Margin—————
Interest Income190K4.9M16.71M20.09M16.61M
Interest Expense0201.36M000
Other Income / Expenses2.12M4.65M16.48M17.94M6.86M
Income Before Tax(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Net Margin—————
EPS (Basic)(1.03)(1.99)(0.83)(0.69)(0.44)
EPS (Diluted)(1.03)(1.99)(0.83)(0.69)(0.44)
Weighted Avg Shares119.1M122.02M150.18M233.82M283.53M
Weighted Avg Shares (Diluted)119.1M122.02M150.18M233.82M283.53M

Erasca, Inc.

NASDAQ:ERAS

Intrinsic Alpha fair value

Locked

Current Price

$13.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.